Corneal transplantation

Aurion Biotech Named “Regenerative Therapeutics Company Of The Year” By BioTech Breakthrough

Retrieved on: 
Wednesday, November 8, 2023
Health, Medical Devices, General Health, Clinical Trials, Pharmaceutical, Optical, Biotechnology, Ophthalmology, Invention, MD, Corneal transplantation, Cell, Aqueous humour, Surgeon, Kyoto Prefectural University of Medicine, Endothelium, Therapy, Patient, Pharmaceutical industry

Aurion Biotech is a clinical stage company that is developing a novel cell therapy to treat patients with corneal endothelial disease, which affects more than 16 million people throughout the world.

Key Points: 
  • Aurion Biotech is a clinical stage company that is developing a novel cell therapy to treat patients with corneal endothelial disease, which affects more than 16 million people throughout the world.
  • Its cell therapy procedure is accessible for ophthalmologists, involving a single administration into the anterior chamber of the patient’s eye.
  • Leveraging the pioneering inventions of Professor Shigeru Kinoshita, MD, of Kyoto Prefecture University of Medicine, Aurion Biotech has acquired the technology for further development.
  • “We are honored to be named BioTech Breakthrough’s ‘Regenerative Therapeutics Company of the Year,’” said Greg Kunst, Aurion Biotech’s CEO.

KeraLink International Unveils Groundbreaking Strategy to Eradicate Corneal Blindness

Retrieved on: 
Monday, August 28, 2023
Foundation, Optical, Health, Philanthropy, International, KLI, Infection, Corneal opacity, Intelligence, Research, Paratriathlon, IKI, Opacity (optics), C corporation, Corneal transplantation, Pharmaceutical industry, Management, Cryptocurrency, Medical imaging, Developing country

KeraLink International (KLI), a globally renowned charitable organization and leader in corneal health innovation, today unveiled three major initiatives to eradicate corneal blindness in low- and middle-income countries (LMICs): supporting the development of a groundbreaking approach to corneal regeneration; advancing a wholistic global strategy for preventing and treating corneal conditions that may lead to blindness; and spearheading a collaborative international effort to combat infectious keratitis, the leading cause of corneal blindness globally.

Key Points: 
  • KeraLink International (KLI), a globally renowned charitable organization and leader in corneal health innovation, today unveiled three major initiatives to eradicate corneal blindness in low- and middle-income countries (LMICs): supporting the development of a groundbreaking approach to corneal regeneration; advancing a wholistic global strategy for preventing and treating corneal conditions that may lead to blindness; and spearheading a collaborative international effort to combat infectious keratitis, the leading cause of corneal blindness globally.
  • “KeraLink International is unique in our singular focus on bringing health care providers, technology innovators, philanthropists, and investors into a coordinated, collaborative effort to eliminate corneal blindness in LMICs,” said Douglas J. Furlong, Board Chairman, KLI.
  • In the U.S., untreated corneal blindness is essentially a condition of the past.
  • Corneal blindness affects 12.7 million children and adults and threatens tens of millions more, even though it is preventable, treatable, and reversible.

SightMD Physicians named 2023 Super Doctors® and Rising Stars

Retrieved on: 
Monday, May 15, 2023
Medicine, Editorial board, Paratriathlon, DO, MD, Patient, Premature, Neuro-ophthalmology, Forehead, World Golf Village, Corneal transplantation, Face, Friends, Orbit, Research, Rockville Centre, New York, Super, Uveitis, Optic nerve, Entrepreneurship, New York Eye and Ear Infirmary, Textbook, Cataract, Abstract, Osteopathic medicine in the United States, Good Samaritan Hospital, Eye, Eyelid, Publishing, Clinical research, Engineering, Microsurgery, Family, Surgeon, CXL, Education, Cross-link, Physician, Hall, Fellow, Pleasure, Rare-earth element, Medical device, Nursing, Dentistry, Veterinary medicine, Ophthalmology, Glaucoma, PRK, Retina, LASIK

HAUPPAUGE, N.Y., May 15, 2023 /PRNewswire-PRWeb/ -- SightMD is excited to announce the growing list of providers that have been named on the 2023 "Super Doctor" and "Super Doctors Rising Stars" lists.

Key Points: 
  • SightMD is excited to announce the growing list of providers that have been named on the 2023 "Super Doctor" and "Super Doctors Rising Stars" lists.
  • HAUPPAUGE, N.Y., May 15, 2023 /PRNewswire-PRWeb/ -- SightMD is excited to announce the growing list of providers that have been named on the 2023 "Super Doctor" and "Super Doctors Rising Stars" lists.
  • said Dr. Baharestani "It is an honor to provide our patients with the highest level oculoplastic surgery services at SightMD."
  • "I am truly honored to be selected as a Super Doctors Rising Star for the 5th year in a row."

Cellusion Announces First Patient Transplanted iPSC-Derived Corneal Endothelial Cell Substitute (CLS001)

Retrieved on: 
Monday, March 27, 2023
Biotechnology, Health, Pharmaceutical, Surgery, Professional Services, Optical, Stem Cells, University, Research, Education, Start-Up, Hospitals, Science, Clinical Trials, Fujita Health University, Cornea, Human, Inc., Society, Safety, Efficacy, Visual impairment, Cataract, Keio University, Paratriathlon, Medicine, Regenerative medicine, Eye, Patient, Water, FIH, Corneal transplantation, Transplant, Visual acuity, IPS, Study, Conference, Endothelium, Disease, Pharmaceutical industry, Dentistry, Ophthalmology

Ph.D., "Cellusion") announced that our research collaborator, Dr. Shigeto Shimmura, Professor of Fujita Health University and Keio University presented at the 22nd Japanese Society for Regenerative Medicine Annual Conference (Kyoto, Japan, March 23-25, 2023) that iPS cell-derived corneal endothelial cell substitute ("CLS001") was transplanted to the first patient (First In Human*, "FIH Study").

Key Points: 
  • Ph.D., "Cellusion") announced that our research collaborator, Dr. Shigeto Shimmura, Professor of Fujita Health University and Keio University presented at the 22nd Japanese Society for Regenerative Medicine Annual Conference (Kyoto, Japan, March 23-25, 2023) that iPS cell-derived corneal endothelial cell substitute ("CLS001") was transplanted to the first patient (First In Human*, "FIH Study").
  • In addition, in terms of the efficacy, he also reported that the visual acuity, central corneal thickness, and minimal corneal thickness has tended to be improved so far.
  • Currently, the only treatment available for this disease is a corneal transplant that replaces normally functioning corneal endothelial cells.
  • Cellusion is developing CLS001, CECSi cells for Corneal Endothelial regeneration to cure Bullous Keratopathy which is applied to more than half of all cases of corneal transplantation.

Eyedea Medical awarded competitive National Science Foundation Phase II Small Business Innovation Research Grant, Baltimore, MD

Retrieved on: 
Thursday, February 23, 2023
NSF, Eye, Descemet membrane endothelial keratoplasty, Paratriathlon, Cornea, Opacity (optics), Patient, DMEK, Corneal opacity, SBIR, Corneal transplantation, National Science Foundation, Phase, Dentistry, Pharmaceutical industry

BALTIMORE, Feb. 23, 2023 /PRNewswire/ -- Eyedea Medical, a Baltimore-based medtech startup working to alleviate the burden of corneal blindness through innovative solutions in corneal transplantation and eye banking, has been awarded a $1,000,000 Phase II Small Business Innovation Research (SBIR) grant from the National Science Foundation (NSF).

Key Points: 
  • BALTIMORE, Feb. 23, 2023 /PRNewswire/ -- Eyedea Medical, a Baltimore-based medtech startup working to alleviate the burden of corneal blindness through innovative solutions in corneal transplantation and eye banking, has been awarded a $1,000,000 Phase II Small Business Innovation Research (SBIR) grant from the National Science Foundation (NSF).
  • Our team believes access to vision care is a human right, and we founded Eyedea Medical to create technologies to help eliminate avoidable blindness.
  • The Phase II award validates our core technology platform and its potential to have a tangible impact on eye care," said Katie Solley, co-founder and CEO of Eyedea Medical.
  • The Phase II award builds off of a previous $225,000 NSF Phase I grant to de-risk the development of Eyedea Medical's first product, DescePrep™.

The Worldwide Therapeutic Contact Lenses Industry is Expected to Reach $4.2 Billion by 2027: Public and Private Initiatives to Increase Vision Care Awareness Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 8, 2023
Health, Optical, Cataract, Bandage, Presbyopia, Edema, Corneal transplantation, Near-sightedness, Keratoconus, Approximation error, Contact, Far-sightedness, Astigmatism, Oxygen, RGP, Lens, Diabetic retinopathy, Cornea, Growth, TCL, Glaucoma, TCL Technology, Ageing, Medical device, Telescopic sight

The global therapeutic contact lenses market is expected to grow at a CAGR of 4.90% from 2021-2027.

Key Points: 
  • The global therapeutic contact lenses market is expected to grow at a CAGR of 4.90% from 2021-2027.
  • The two most common contact lens variants available in the therapeutic contact lenses market include hard and soft contact lenses.
  • RGP contact lenses are the most common type of hard contact lenses available in the industry.
  • What factors impact the growth of the therapeutic contact lenses market?

Insights on the Therapeutic Contact Lenses Global Market to 2027 - Increase in Silicone Hydrogel Contact Lenses Application Presents Opportunities

Retrieved on: 
Thursday, February 9, 2023
Bausch, Human services, Corneal transplantation, Dailies, Near-sightedness, Keratoconus, Bausch & Lomb, Approximation error, Johnson & Johnson Vision, ACUVUE, RGP, Eye, Diabetic retinopathy, Cornea, Cooper, TCL, Glaucoma, Soft, AR, Presbyopia, Alcon, Korea Disease Control and Prevention Agency, Johnson & Johnson, Lens, CDC, City, Growth, Elasticity, Ophthalmology, The Cooper Companies, Wetting, Augmented reality, Government, Edema, Urbanization, Far-sightedness, Patient, Oxygen, CooperVision, Research, Risk, Ageing, Cataract, Bandage, Contact, Astigmatism, BCL, ULTRA, Sihi Kahi Chandru, Augment, Acuvue, TCL Technology, Medical device, Camera, Telescopic sight, Agriculture, Pharmaceutical industry, Silicone, EU

The global therapeutic contact lenses market is expected to grow at a CAGR of 4.90% from 2021-2027.

Key Points: 
  • The global therapeutic contact lenses market is expected to grow at a CAGR of 4.90% from 2021-2027.
  • The two most common contact lens variants available in the therapeutic contact lenses market include hard and soft contact lenses.
  • RGP contact lenses are the most common type of hard contact lenses available in the industry.
  • Many key players in the therapeutic contact lenses market do offer Silicone hydrogel therapeutic contact lenses, such as Acuvue Oasys (Johnson & Johnson Vision Care), Air Optix Aqua (Alcon), Biofinity (CooperVision), and PureVision2 (Bausch & Lomb).

Detroit Free Press names Eversight a winner of the Michigan Top Workplaces 2022 award

Retrieved on: 
Monday, November 21, 2022
Well, Human, Environment, Workplace, Corneal transplantation, Organization, Academic health science centre, Trust, Eye, Employee Appreciation Day, Workforce, Detroit Free Press, Transplant, ANN, Surgeon, Research, Severe cognitive impairment, Management

ANN ARBOR, Mich., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Eversight , a nonprofit eye bank dedicated to restoring sight and preventing blindness worldwide through donation, transplantation and research, has been named a 2022 Top Workplace in Michigan through the Detroit Free Press Top Workplaces competition .

Key Points: 
  • ANN ARBOR, Mich., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Eversight , a nonprofit eye bank dedicated to restoring sight and preventing blindness worldwide through donation, transplantation and research, has been named a 2022 Top Workplace in Michigan through the Detroit Free Press Top Workplaces competition .
  • This recognition is based solely on employee feedback gathered through a third-party survey administered by employee engagement technology partner, Energage LLC .
  • The confidential survey uniquely measures 15 culture drivers that are critical to the success of any organization, including alignment, execution and connection.
  • In October, Eversight won three Top Workplaces National Culture Excellence awards in the areas of Employee Appreciation, Employee Well-Being and being a Woman-Led organization.

Kala Pharmaceuticals Announces Appointment of Marjan Farid, M.D., to its Board of Directors

Retrieved on: 
Tuesday, November 1, 2022
Biologically based mental illness, Marketing, Security (finance), Severe cognitive impairment, Nasdaq, Board of directors, Textbook, U.S. Securities and Exchange Commission, Health, Ophthalmology, University of California, San Francisco Fetal Treatment Center, American Society of Cataract and Refractive Surgery, GLOBE, Research, Industry, Board, Society, COVID-19, Physician, Program, Stargardt disease, University of California, San Diego Performance-Based Skills Assessment, UCI, University of California, Irvine, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Eye, Education, Pathology, Coronavirus, University, NASDAQ, Cataract surgery, Private Securities Litigation Reform Act, KALA, Cataract, Refraction, Patient, Food, Corneal transplantation, Retinitis pigmentosa, Pharmaceutical industry, Biology

ARLINGTON, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ: KALA) (Kala or the Company), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced the appointment of Marjan Farid, M.D., to its Board of Directors.

Key Points: 
  • ARLINGTON, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ: KALA) (Kala or the Company), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced the appointment of Marjan Farid, M.D., to its Board of Directors.
  • Marjan is an outstanding addition to our Board of Directors.
  • She performs limbal stem cell transplants as well as artificial corneal transplantation for the treatment of patients with severe ocular surface disease.
  • Kala is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye.

Aurion Biotech Wins Prestigious Prix Galien Startup Award

Retrieved on: 
Thursday, October 27, 2022
Biotechnology, Pharmaceutical, Optical, Health, Wyeth, Ophthalmology, Endothelial dysfunction, Fortune 1000, CEO, The Hills Have Eyes 2, Endothelium, Physician, Alcon, Transplant, Paganini Competition, Patient, Petrichor, Multimedia, Cornea, Corneal transplantation, Digital health, Hoffmann-La Roche, Medicine, Former, Nobel Prize, Health, Pharmaceutical industry, Biotechnology, Incubator

Aurion Biotech , whose mission is to restore vision to millions of patients with its life-changing regenerative therapies, today announced it has won the prestigious Prix Galien Award for Best Startup in Biotech / Pharma.

Key Points: 
  • Aurion Biotech , whose mission is to restore vision to millions of patients with its life-changing regenerative therapies, today announced it has won the prestigious Prix Galien Award for Best Startup in Biotech / Pharma.
  • Aurion Biotech received the Best Start-up in Biotech / Pharma award, one of six different award categories, and was chosen from more than 146 products from 129 nominee companies, spanning 14 therapeutic areas.
  • The vetting process was rigorous: nominees are invited to apply for the Prix Galien award.
  • According to the Galien Foundation, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical research.